VIC 2023 Mid-Year Report
Despite the difficult fundraising environment currently existing nationwide, VIC’s portfolio of companies made impressive progress in the first half of 2023.
Solaris Vaccines Awarded Funding from NIH to Develop Novel Influenza Vaccine using SolaVAX™ Platform
This NIAID SBIR will evaluate an innovative approach for producing superior vaccines more quickly and cost-effectively. FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that it has received a Small Business...
Solenic Medical, Inc. Announces $5.1M Series A Funding Round Led by Johnson & Johnson Innovation – JJDC, Inc.
Solenic accelerates their mission to treat patients suffering from acute or chronic prosthetic joint infections (PJI). ADDISON, TEXAS – Solenic Medical, developer of a device that uses alternating magnetic fields (AMF)...
The Advantages of Investing in Venture Creation Firms Like VIC Tech
In the world of early stage investing, traditional venture capital funds have long been the go-to option for investors seeking exposure to high-growth opportunity companies. However, a different investment model is...
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Thank you for taking the time to speak with us, Dr. Clark. Please tell us about your education and professional experience.
Nob Hill Therapeutics Selected for Featured Poster Presentation at Respiratory Innovation Summit
Albuquerque, NM, May 19, 2023 – Nob Hill Therapeutics (NHT), an inhalation technology company, today announced that it has been selected to be a featured poster presentation at the ATS 2023 Respiratory Innovation Summit...
VIC Foundry Awarded Phase I SBIR Grant from the National Institutes of Health
NIH Grant is to Develop a Portable Sample Preparation Device for Concentration and Recovery of Bacterial Contaminants
Direct-to-Phase II SBIR Grant from NIH Awarded to Neurexis Therapeutics to Evaluate Neuroprotective Therapeutic in Stroke Preclinical Assessment Network (SPAN)
A promising approach for preventing cognitive and behavioral impairment following ischemia Aurora, CO - Neurexis Therapeutics, Incorporated, announces it has been awarded $900,000 in funding from a Direct-to-Phase II...
Solaris Vaccines Adds Izabela Ragan as Director of Research and Development for the SolaVAX™ Platform
FORT COLLINS, CO – Solaris Vaccines, Inc. announced today that Dr. Izabela Ragan (DVM, PhD), an expert in novel vaccine technologies, has joined as Director of Research and Development. The Company is developing a...
Intellectual Property Landscape Analysis Using Free Patent Databases
For an investor seeking a decision on whether or not to invest in an innovation-based startup, there are numerous factors they need to take into consideration. Some of the most important questions that need to be...
